
Doctor Roger J Hajjar
Mass General Brigham, Boston (United States of America)
Membership:
ESC Professional Member
HFA Member
Follow
Biography
Dr. Roger Hajjar is the Director of the Gene and Cell Therapy Institute at Mass General Brigham in Boston, Massachusetts. He has been at the forefront of the development and translation of cardiac gene therapy from early-stage research through to clinical trials. Under his leadership, his laboratory has identified and validated multiple cardiac therapeutic targets, which have culminated in the successful initiation and completion of First-in-Human gene therapy clinical trials for patients suffering from various forms of heart failure and cardiomyopathies. Dr. Hajjar is the co- founder of several gene therapy enterprises, including Nanocor/AskBio and Medera, which are actively advancing therapeutic programs targeting both rare and prevalent forms of cardiomyopathy.
Contributor content
Presentation
Targets for gene therapy in heart failure and cardiomyopathies
Presentation
NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure
Presentation
Gene therapy for heart failure
Presentation
Gene therapy to target calcium cycling in heart failure.
Presentation
Genome engineering of iPS-derived cardiomyocytes.
Presentation

